Please assess the completion status of the following clinical trial:

Trial Title: Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria :~* Aged 2 to 45 years on the day of inclusion.~* Provision of Informed Consent/Assent Form signed by the participant (and/or by the parent or another legally acceptable representative for participants \<18 years).~* Participant (and parent/guardian for participants \<18 years) able to attend all scheduled visits and to comply with all trial procedures.~* For a female participant of child-bearing potential, avoid becoming pregnant (use of an effective method of contraception or abstinence) for at least 4 weeks prior to the first vaccination, until at least 4 weeks after the last vaccination.~* Participant in good health, based on medical history, physical examination and laboratory parameters.~Exclusion Criteria :~* Personal or family history of thymic pathology (thymoma), thymectomy, or myasthenia.~* For a female participant of child-bearing potential, known pregnancy or positive serum pregnancy test at Screening.~* For a female participant of child-bearing potential, known pregnancy or positive urine pregnancy test on the day of the first injection.~* Breast-feeding female participant.~* Receipt of any vaccine in the 4 weeks preceding the first trial vaccination.~* Human immunodeficiency virus, hepatitis B, or hepatitis C seropositivity in the blood sample taken at screening.~* Planned participation in another clinical trial during the first year of the study.~* Known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the past 6 months, or long-term systemic corticosteroids therapy.~* Known systemic hypersensitivity to any of the vaccine components or history of a life-threatening reaction to the trial vaccines or to a vaccine containing any of the same substances.~* Chronic illness at a stage that could interfere with trial conduct or completion, in the opinion of the Investigator.~* Current alcohol abuse or drug addiction that may interfere with the participant's ability to comply with trial procedures.~* Receipt of blood or blood-derived products in the past 3 months that might interfere with the assessment of immune response.~* Participant deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized without his/her consent.~* Laboratory abnormalities of at least moderate severity or clinically significant according to the Investigator in blood sample taken at screening.~* Participation in another clinical trial investigating a vaccine, drug, medical device, or a medical procedure in the 4 weeks preceding the first trial vaccination.~* Planned receipt of any vaccine in the 4 weeks following the first trial vaccination.~* Familial atopy medical history (parents, brothers, or sisters).~* Previous vaccination with meningococcal A+C or typhoid vaccines within 3 years prior to inclusion.~* History of meningococcal or typhoid infections (confirmed either clinically, serologically or microbiologically).

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- CYD Dengue Vaccine Group (Type: EXPERIMENTAL): Participants who received CYD dengue vaccine as first (Day 0), second (Day 0 + 6 months), and third (Day 0 + 12 months) injections. Participants were followed for 4 years after the third injection.
- Control Vaccine Group (Type: SHAM_COMPARATOR): Participants who received the Meningococcal Polysaccharide Vaccine A + C, placebo, and Typhoid Vi polysaccharide vaccine as the first (Day 0), second (Day 0 + 6 months), and third (Day 0 + 12 months) injections, respectively. Participants were followed for 4 years after the third injection.

Based on this trial design, predict the completion outcome and termination type (if applicable).